Resistance profile of osimertinib in pre-treated patients with EGFR T790M-mutated non-small cell lung cancer

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Maria Gabriela O. Fernandes (Author) FMUP; Catarina Sousa (Author) Other; Maria Jacob (Author) Other; Leonor Almeida (Author) Other; Vanessa Santos (Author) Other; David Araújo (Author) Other; Hélder Novais Bastos (Author) FMUP; Adriana Magalhães (Author) Other; Luís Cirnes (Author) Other; Conceição Souto Moura (Author) Other; Henrique Queiroga (Author) FMUP; Natália Cruz-Martins (Author) FMDUP; Venceslau Hespanhol (Author) FMUP

Journal

Title: Frontiers in Oncology

Vol. 11 No. Article 602924

ISSN: 2234-943X

Publisher: Frontiers Media

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 1 Citation

Other information

Authenticus ID: P-00T-Z8Z

DOI: 10.3389/fonc.2021.602924

Abstract (EN): Background: Osimertinib efficacy in pre-treated patients with epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been demonstrated in clinical trials, but real-world data, particularly regarding resistance profile, remains limited. This study aims to analyze the resistance mechanisms acquired after treatment with Osimertinib. Methods: Clinical outcomes and molecular results from re-biopsies at the time of osimertinib progression of EGFR T790M-mutated NSCLC patient were analyzed. Results: Twenty-one patients with stage IV adenocarcinoma were included [median 69 years; 57.1% female; 85.7% never-smokers; 23.8% ECOG performance status (PS) >= 2]. Median PFS and OS were 13.4 (95% CI: 8.0-18.9) and 26.4 (95% IC: 8.9-43.8) months, respectively. At the time of analysis, 10 patients had tumor progression (47.6%). T790M loss occurred in 50%, being associated with earlier progression (median PFS 8.1 vs. 21.4 months, p = 0.011). Diverse molecular alterations were identified, including C797S mutation (n = 1), PIK3CA mutation (n = 2), MET amplification (n = 1), CTNNB1 mutation (n = 1), and DCTN1-ALK fusion (n = 1). Histological transformation into small cell carcinoma occurred in one patient. Conclusions: This real-world life study highlights the relevance of re-biopsy at the time of disease progression, contributing to understand resistance mechanisms and to guide treatment strategies.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 7